Past Issues
See what you've been missing. Browse every issue of our free, daily briefing.
A senator bet his life on an "undruggable" cancer drug. The data just landed.
A former U.S. senator enrolled in a trial for a drug that scientists said couldn't exist, and Phase 3 results show pancreatic cancer patients living nearly twice as long as those on chemo. Meanwhile, the FDA just sent 2,200 companies a not-so-friendly reminder about their missing trial data.
Lilly just paid $300M for a company with zero drugs in humans
Eli Lilly dropped up to $300 million on a two-year-old startup that hasn't tested a single drug in people. Meanwhile, AbbVie is shopping for painkillers in China, two obesity and proteomics companies want nearly $700M combined from public markets, and Big Pharma quietly took out the immunology trash.
The protein that stumped cancer researchers for 40 years just lost a fight
A cancer target that scientists literally gave up on just got beaten in a Phase 3 trial, with results so strong they might reshape oncology's most stubborn tumor types. Plus: the FDA fast-tracks a guided-missile drug for the deadliest lung cancer, Regeneron crashes the radioactive drug party, and two biotechs ring the IPO bell on the same day.
Western pharma went on a China biotech shopping spree to start 2026
Big Pharma is buying Chinese biotech innovation at a pace that would make Black Friday shoppers blush, pouring billions into licensing deals before most people finished their New Year's resolutions. Meanwhile, Gilead announced $13 billion in deals in six weeks, the FDA blessed a needle-free weight loss pill, and biotech's IPO window is officially back open.
The FDA rejected this melanoma drug twice, even with breakthrough status
A cancer drug with genuinely impressive data just got its second FDA rejection, and the reason has nothing to do with whether it works. Meanwhile, a single canceled FDA meeting killed an entire biotech company. Grab your coffee; today's newsletter is a masterclass in regulatory risk.
A cancer therapy just wiped out three autoimmune diseases in one patient
A woman who needed daily blood transfusions had three autoimmune diseases erased by a single CAR-T infusion. Her immune system essentially rebooted itself. Meanwhile, gut bacteria might be giving people ALS, biotech VCs are having an existential crisis, and the nation's top health official has a peptide problem.
Roche just bought 2,176 GPUs. That's more than some countries own.
Roche built the biggest supercomputer in pharma history, and it's not even close. Meanwhile, two pharma giants placed billion-dollar bets on protein degradation within 24 hours of each other, and the GLP-1 price war just entered a new phase that could change how 40% of American adults access obesity drugs.
The FDA's favorite AI tool just got banned from U.S. healthcare
The most safety-conscious AI company in tech got kicked out of every federal health agency, not for a security flaw, but for telling the Pentagon "no." Meanwhile, Europe wrote its biggest biotech check ever, and a condition with zero approved drugs just found its first real lead.
Gilead turns a $20M option deal into a major ADC bet
Gilead's exclusive option and license agreement with a Munich startup most people have never heard of caps a wild week of billion-dollar dealmaking, FDA dysfunction that literally killed a company, and AI making moves that blur the line between tech firm and drug developer. Buckle up.
Big pharma dropped $20B in March alone, and April's not slowing down
Three mega-acquisitions worth over $20 billion landed in a single month, making March 2026 one of the most frenzied stretches of biotech dealmaking in recent memory. Meanwhile, the White House is using 100% drug tariffs as a bargaining chip, a stealth oncology startup just debuted with $100 million, and scientists found a single protein that actually reverses brain aging in mice.
The FDA just approved a drug that sneaks past the brain's bouncer
A rare disease therapy just pulled off something no enzyme replacement has done before: crossing the blood-brain barrier. Meanwhile, the FDA commissioner wants to rewrite the rulebook on drug approvals, MIT open-sourced an AI that screens drugs 1,000x faster, and GSK poached Sanofi's top vaccine scientist.
The drug pipeline just shrank for the first time in 30 years
For three decades, the global biopharma pipeline did exactly one thing: grow. That streak just ended, and the forces behind the reversal tell a much bigger story about where the industry is headed. Plus: a $15 billion budget threat, Big Pharma's tariff escape hatch, and a CAR-T milestone.
Lilly's $25/month obesity pill just killed the needle era
The FDA just approved an obesity pill that costs less than your Netflix subscription, and it doesn't require a single needle. Meanwhile, the White House is threatening to double the price of imported drugs overnight, and a gene editor that works like a pencil just aced the biggest test in medicine.
Gilead just killed its weekly HIV pill after an FDA safety hold
The company that basically owns the HIV market just scrapped a trial that was supposed to be the next big thing in patient convenience. Meanwhile, a lung drug is pulling double duty in a disease it was never designed for, and 8,000 clinical trial sites just went dark in the Middle East.
Lilly drops $7.8B on a sleep drug company most people have never heard of
Big Pharma went on a $13 billion shopping spree on Monday, with Lilly and Biogen each writing massive checks for very different bets. Meanwhile, an entirely new class of genetic medicine just entered the clinic for the first time, and a cancer vaccine startup filed for total liquidation. Buckle up.
J&J paid $16.6B for a heart pump. Two trials just failed.
Johnson & Johnson's crown jewel cardiac device flopped in two major clinical trials, raising hard questions about a $16.6 billion acquisition. Meanwhile, Merck had a very busy week: unveiling a cholesterol pill that could retire the needle and dropping $6.7 billion on an early-stage cancer drug.
Lilly just bet $2.75B that AI can find its next blockbuster drug
Eli Lilly went from quietly licensing AI software to writing a $2.75 billion check to the same company in under three years. Meanwhile, a hypertension drug worked so well on a single dose that it accidentally ruined its own clinical trial. It's been that kind of week in biotech.
A biotech lost half its value over 0.9%. Yes, zero-point-nine.
Wave Life Sciences posted a 14% drop in visceral fat and actually preserved muscle mass. Investors rewarded them by torching 50% of the company's market cap in a single session. Meanwhile, scientists in China made cancer-killing eye drops from pig semen, and somehow that's not even the wildest story today.
The FDA just turned 365 insulin shots into 52. Here's what that means.
The first weekly insulin just got FDA approval, and it might be the biggest shake-up in diabetes care since, well, insulin itself. Meanwhile, a drug class everyone left for dead just showed signs of life, Big Pharma made a major psychedelics bet, and someone is fighting pancreatic cancer with electricity.
The FDA rejected this gene therapy twice. It just got approved anyway.
A gene therapy for a disease that kills 75% of kids before age two finally won FDA approval, but only after being rejected twice for reasons that had nothing to do with whether it works. Meanwhile, Novartis is spending $2 billion to replace its own blockbuster, and Pfizer's Lyme vaccine aced the test but forgot to fill in the right bubble.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.